These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 30836093)

  • 21. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
    Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
    J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
    J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
    Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
    Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
    Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response.
    Mücke VT; Thomas D; Mücke MM; Waidmann O; Zeuzem S; Sarrazin C; Pfeilschifter J; Vermehren J; Finkelmeier F; Grammatikos G
    Liver Int; 2019 Nov; 39(11):2174-2183. PubMed ID: 31207039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West.
    Dang H; Yeo YH; Yasuda S; Huang CF; Iio E; Landis C; Jun DW; Enomoto M; Ogawa E; Tsai PC; Le A; Liu M; Maeda M; Nguyen B; Ramrakhiani N; Henry L; Cheung R; Tamori A; Kumada T; Tanaka Y; Yu ML; Toyoda H; Nguyen MH
    Hepatology; 2020 Jun; 71(6):1910-1922. PubMed ID: 31610027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
    Ohama H; Hiraoka A; Tada T; Kariyama K; Itobayashi E; Tsuji K; Ishikawa T; Toyoda H; Hatanaka T; Kakizaki S; Naganuma A; Tada F; Tanaka H; Nakamura S; Nouso K; Tanaka K; Kumada T;
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1394-1402. PubMed ID: 38602340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
    Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
    World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
    Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Turgeon MK; Shah SA; Delman AM; Tran BV; Agopian VG; Wedd JP; Magliocca JF; Kim A; Cameron A; Olyaei A; Orloff SL; Anderson MP; Kubal CA; Cannon RM; Locke JE; Simpson MA; Akoad ME; Wongjirad CP; Emamaullee J; Moro A; Aucejo F; Feizpour CA; Vagefi PA; Nguyen MH; Esquivel CO; Dhanireddy K; Subramanian V; Chavarriaga A; Kazimi MM; Anderson MS; Sonnenday CJ; Kim SC; Foley DP; Abdouljoud M; Salgia RJ; Moris D; Sudan DL; Ganesh SR; Humar A; Doyle M; Chapman WC; Maithel SK
    Ann Surg; 2021 Oct; 274(4):613-620. PubMed ID: 34506316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders.
    Isfordink CJ; van Erpecum KJ; Fischer K; van der Valk PR; van Vulpen LFD; Schutgens REG; Arends JE; Mauser-Bunschoten EP
    Haemophilia; 2023 Jan; 29(1):106-114. PubMed ID: 36184751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND
    Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals.
    Degasperi E; Galmozzi E; Facchetti F; Farina E; D'Ambrosio R; Soffredini R; Iavarone M; Lampertico P
    J Viral Hepat; 2019 Oct; 26(10):1233-1236. PubMed ID: 31177595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
    Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
    Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
    Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals.
    Tanaka S; Shinkawa H; Tamori A; Takemura S; Takahashi S; Amano R; Kimura K; Ohira G; Kawada N; Kubo S
    J Surg Oncol; 2020 Dec; 122(8):1543-1552. PubMed ID: 32856301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
    Roche B; Coilly A; Duclos-Vallee JC; Samuel D
    Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.